Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHAMPS Study Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CHAMPS Study Group,
Related Collections
Right arrow All Imaging
Right arrow MRI
Right arrow Volumetric MRI
Right arrow All Clinical trials
Right arrow Multiple sclerosis

Neurology 2002;59:998-1005
© 2002 American Academy of Neurology

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

CHAMPS Study Group

Address correspondence and reprint requests to Dr. Jack H. Simon, Department of Radiology, University of Colorado Health Sciences Center, Campus Box A-034, 4200 E. Ninth Ave., Denver, CO 80262; e-mail: jack.simon{at}uchsc.edu

Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event.

Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months.

Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months.

Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.




This article has been cited by other articles:


Home page
 Mult SclerHome page
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J.C. McHugh, P.L. Galvin, and R.P. Murphy
Retrospective comparison of the original and revised McDonald criteria in a general neurology practice in Ireland
Multiple Sclerosis, January 1, 2008; 14(1): 81 - 85.
[Abstract] [PDF]

Home page
 Mult SclerHome page
V. Tomassini, L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, and C. Pozzilli
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
Multiple Sclerosis, November 1, 2007; 13(9): 1086 - 1094.
[Abstract] [PDF]

Home page
 IOVSHome page
A. Klistorner, S. Graham, C. Fraser, R. Garrick, T. Nguyen, M. Paine, J. O'Day, J. Grigg, H. Arvind, and F. A. Billson
Electrophysiological Evidence for Heterogeneity of Lesions in Optic Neuritis
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4549 - 4556.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
J H Simon
Brain atrophy in multiple sclerosis: what we know and would like to know
Multiple Sclerosis, November 1, 2006; 12(6): 679 - 687.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
C. Fraser, A. Klistorner, S. Graham, R. Garrick, F. Billson, and J. Grigg
Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis.
Arch Neurol, June 1, 2006; 63(6): 847 - 850.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J.H. Simon, D. Li, A. Traboulsee, P.K. Coyle, D.L. Arnold, F. Barkhof, J.A. Frank, R. Grossman, D.W. Paty, E.W. Radue, et al.
Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines.
AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 455 - 461.
[Full Text] [PDF]

Home page
 BrainHome page
P. Pantano, C. Mainero, D. Lenzi, F. Caramia, G. D. Iannetti, M. C. Piattella, I. Pestalozza, S. Di Legge, L. Bozzao, and C. Pozzilli
A longitudinal fMRI study on motor activity in patients with multiple sclerosis
Brain, September 1, 2005; 128(9): 2146 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
I F Pestalozza, C Pozzilli, S Di Legge, M C Piattella, P Pantano, F Caramia, P Pasqualetti, and G L Lenzi
Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome
Multiple Sclerosis, August 1, 2005; 11(4): 390 - 394.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. J. Carmosino, K. M. Brousseau, D. B. Arciniegas, and J. R. Corboy
Initial Evaluations for Multiple Sclerosis in a University Multiple Sclerosis Center: Outcomes and Role of Magnetic Resonance Imaging in Referral
Arch Neurol, April 1, 2005; 62(4): 585 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C. H Polman, J. S Wolinsky, and S. C Reingold
Multiple sclerosis diagnostic criteria: three years later
Multiple Sclerosis, February 1, 2005; 11(1): 5 - 12.
[Abstract] [PDF]

Home page
 BrainHome page
D.-A. Laplaud, C. Ruiz, S. Wiertlewski, S. Brouard, L. Berthelot, M. Guillet, B. Melchior, N. Degauque, G. Edan, P. Brachet, et al.
Blood T-cell receptor {beta} chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution
Brain, May 1, 2004; 127(5): 981 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. Minneboo, F. Barkhof, C. H. Polman, B. M. J. Uitdehaag, D. L. Knol, and J. A. Castelijns
Infratentorial Lesions Predict Long-term Disability in Patients With Initial Findings Suggestive of Multiple Sclerosis
Arch Neurol, February 1, 2004; 61(2): 217 - 221.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. H. Simon and A. J. Thompson
Is multiple sclerosis still a clinical diagnosis?
Neurology, September 9, 2003; 61(5): 596 - 597.
[Full Text] [PDF]

Home page
 NeurologyHome page
E. M. Frohman, D. S. Goodin, P. A. Calabresi, J. R. Corboy, P. K. Coyle, M. Filippi, J. A. Frank, S. L. Galetta, R. I. Grossman, K. Hawker, et al.
The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, September 9, 2003; 61(5): 602 - 611.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.